000 | 01247na a2200181 4500 | ||
---|---|---|---|
999 |
_c1660 _d1660 |
||
003 | PC1660 | ||
005 | 20210625062756.0 | ||
008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_91010 _aPablos Álvarez, José Luis _eReumatología |
||
245 | 0 | 0 |
_aBiologic therapy in rheumatoid arthritis. _h[artículo] |
260 |
_bCurrent Topics in Medicinal Chemistry, _c2013 |
||
300 | _a13(6):752-9. | ||
500 | _aFormato Vancouver: Cañete JD, Pablos JL. Biologic therapy in rheumatoid arthritis. Curr Top Med Chem. 2013;13(6):752-9. | ||
501 | _aPMID: 23574524 | ||
504 | _aContiene 87 referencias | ||
520 | _aBiologic therapies have notably improved the treatment of RA, making disease remission a realistic goal. After more than ten years of experience, the safety issues associated with these drugs are well characterized and can be avoided with careful patient selection and tight clinical control. Although the different biologic drugs (anti-TNF agents, anti-IL-6, anti-B cells and anti-costimulation of T-cells) have apparently different mechanisms of action, all biologic agents have demonstrated similar efficacy. In addition results of the combination of two biologic therapies have shown no additive clinical effects, although there is an increased risk of infection. Therefore, further research is needed to optimize the use of these and future targeted therapies in RA. | ||
710 |
_9123 _aServicio de Reumatología |
||
710 |
_9625 _aInstituto de Investigación imas12 |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1660.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |